Novavax (XSWX:NVAX) Moat Score: 5/10 (As of Jul. 07, 2026)


XSWX:NVAX Novavax Inc XSWX:NVAX
50 GF Score
Price CHF7.61
GF Value CHF3.14
! 7 Warning Signs
View Full Analysis

What is Novavax Moat Score?

Novavax XSWX:NVAX -1.78% 50 Moat Score is 5 as of Jul. 07, 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 50/100 and a GF Value™ of CHF3.14. The stock has 7 warning signs investors should review. Among 1,394 Biotechnology companies, Novavax ranks better than 96.7% on this metric.

Novavax has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Novavax has Narrow Moat: Novavax Inc has a solid narrow moat due to its valuable intellectual property and patents in the vaccine industry. The company benefits from some regulatory barriers and R&D capabilities, but lacks strong customer loyalty and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Novavax might have Narrow Moat - Solid narrow moat.

Novavax  (XSWX:NVAX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Novavax Moat Score Related Terms

XSWX:NVAX vs MPLT, COAG, INBX: Moat Score Comparison

For the Biotechnology subindustry, Novavax's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novavax Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Moat Score distribution charts can be found below:

* The bar in red indicates where Novavax's Moat Score falls into.


XSWX:NVAX
50GF Score
Novavax Inc XSWX:NVAX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Novavax (XSWX:NVAX) has a Moat Score of 5 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Novavax ranks #46 out of 1394 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Novavax's Moat Score too high?
Novavax's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Novavax's value of 5 is 150% above this industry median. Based on the distribution chart, Novavax ranks #46 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Moat Score compare to MPLT and COAG?
According to the Biotechnology industry distribution chart, Novavax ranks #46 out of 1394 companies for Moat Score. This places Novavax in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Novavax's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novavax's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novavax's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Moat Score of 5. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Moat Score is 5 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.

Key valuation signals for XSWX:NVAX:

  • Moat Score: 5
  • GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
  • GF Score™: 50/100 with 7 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1394)

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for XSWX:NVAX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.61
Price
CHF3.14
GF Value